Featured Publications
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusionThe Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA, Sanacora G. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal Of Psychiatry 2017, 175: 150-158. PMID: 28969441, PMCID: PMC5794524, DOI: 10.1176/appi.ajp.2017.17040472.Peer-Reviewed Original ResearchConceptsIndividual participant dataLong-term safetySuicidal ideationKetamine effectsSingle doseParticipant dataSuicide itemOutcome measuresSystematic reviewIndividual Participant Data Meta-AnalysisLimited treatment optionsPrimary outcome measureSelf-reported outcome measuresData Meta-AnalysisIntravenous ketaminePublic health crisisKetamine administrationTreatment optionsQIDS-SRDepressed patientsDepressive symptomsIntervention studiesKetamineMeta-AnalysisSuicidal thoughtsEfficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer J, Landeros-Weisenberger A, Johnson J, Londono Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2022, 20: 241-251. PMID: 37153136, PMCID: PMC10153503, DOI: 10.1176/appi.focus.22020004.Peer-Reviewed Original ResearchTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2019
Randomized, Sham-Controlled Trial of Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Tics in Adolescents With Tourette Syndrome
Sukhodolsky DG, Walsh C, Koller WN, Eilbott J, Rance M, Fulbright RK, Zhao Z, Bloch MH, King R, Leckman JF, Scheinost D, Pittman B, Hampson M. Randomized, Sham-Controlled Trial of Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Tics in Adolescents With Tourette Syndrome. Biological Psychiatry 2019, 87: 1063-1070. PMID: 31668476, PMCID: PMC7015800, DOI: 10.1016/j.biopsych.2019.07.035.Peer-Reviewed Original ResearchConceptsSupplementary motor areaYale Global Tic Severity ScaleFunctional magnetic resonanceTic Severity ScaleReal-time functional magnetic resonanceTourette syndromeSeverity ScaleYale Global Tic Severity Scale-Total Tic ScoreTotal tic scorePrimary outcome measureSham control conditionReduction of ticsMagnetic resonanceSecondary outcomesSessions of neurofeedbackCrossover studyTic symptomsTic scoreOutcome measuresMotor areaSecondary measuresTic severityReal neurofeedbackEnd pointNeurofeedback intervention
2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16
2014
Prognostic subgroups for citalopram response in the STAR*D trial.
Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR*D trial. The Journal Of Clinical Psychiatry 2014, 75: 738-47. PMID: 24912106, PMCID: PMC4471174, DOI: 10.4088/jcp.13m08727.Peer-Reviewed Original ResearchConceptsMajor depressive disorderBaseline clinical characteristicsClinical characteristicsTreatment successTreatment outcomesTreatment responseSide effectsSelective serotonin reuptake inhibitor (SSRI) pharmacotherapyEarly symptom improvementInitial clinical characteristicsOpen-label citalopramPrimary outcome measureFirst treatment phasePast treatment historySequenced Treatment AlternativesDSM-IV diagnosisTraditional psychiatric diagnosesDifferential treatment outcomesSSRI treatmentSymptom improvementMDD patientsMedication responsePoor responseDepressive disorderPrognostic subgroups
2013
Meta-Analysis
Mulqueen JM, Bartley CA, Bloch MH. Meta-Analysis. Journal Of Attention Disorders 2013, 19: 118-124. PMID: 24071773, DOI: 10.1177/1087054713504135.Peer-Reviewed Original ResearchConceptsMedication managementBehavioral interventionsPrimary outcome measureTreatment of ADHDControl conditionCochrane LibraryADHD Rating ScaleOutcome measuresMean improvementEfficacious treatmentSide effectsMeta-AnalysisParental interventionRating ScaleFinal analysisRelative efficacyInterventionYoung childrenPreliminary evidenceParent interventionPreschool childrenTrialsEfficacyADHDParental preferences
2011
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Molecular Psychiatry 2011, 17: 1272-1282. PMID: 21931319, PMCID: PMC3625950, DOI: 10.1038/mp.2011.100.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialMajor depressive disorderBaseline depression severityDepression severityPublication biasMethodological qualityGreater baseline depression severityDocosahexaenoic acidEicosapentaenoic acidTrial methodological qualityPrimary outcome measureNon-significant benefitTreatment of depressionLow methodological qualityFatty acid treatmentTreat analysisDepressive disorderMajor depressionSources of heterogeneityOutcome measuresClinical measuresTreatment efficacySystematic reviewSecondary analysisStudy participants
2007
Systematic Review: Pharmacological and Behavioral Treatment for Trichotillomania
Bloch MH, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner R, Nudel J, Pittenger C, Leckman JF, Coric V. Systematic Review: Pharmacological and Behavioral Treatment for Trichotillomania. Biological Psychiatry 2007, 62: 839-846. PMID: 17727824, DOI: 10.1016/j.biopsych.2007.05.019.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsHabit reversal therapyTreatment of trichotillomaniaCochrane Central RegisterPrimary outcome measureClinical rating scalesNon-specific effectsSSRI pharmacotherapyCentral RegisterControlled TrialsRelevant trialsReuptake inhibitorsTreat analysisPharmacotherapy studiesBlinded assessmentClinical trialsTrichotillomania severityMean changeOutcome measuresFuture therapiesElectronic databasesLarger sample sizeRigorous control conditionsPsychiatric conditionsSystematic review